6
Tetrahedron
stirred 14 h at RT. Purification gave a brown red solid (13.6 mg,
extracted by CHCl3:iPrOH solution (4 x 10 mL; 85:15). The
ACCEPTED MANUSCRIPT
26%, HPLC purity: 94.7%;19 decomp. at 117 °C): Rf 0.18
(CH2Cl2:MeOH 10:1); νmax (neat): 3387w, 2926m, 2361m,
2178w, 1623s, 1597s, 1501s, 1428s, 1373m, 1349m, 1295m,
1255s, 1182m, 1096s, 973m, 921m, 806w, 771m, 723s, 697s,
652w; 1H NMR (500 MHz, CDCl3): δ = 7.84–7.87 (2H, m,
combined organic layer was dried over Na2SO4, filtered and
concentrated in vacuo. Column chromatography with 100%
CH2Cl2 to CH2Cl2:MeOH 100:2 to 100:5 to 100:8 to 100:9 gave
the product.
3
4.4. Synthesis of Acridinium Dyes and 9,10-Dihydroacridin-9-ols
C3”H, C5”H), 7.76–7.79 (1H, m, C4”H), 7.58 (1H, dd, J 8.6,
8.3, C6H), 7.38–7.43 (5H, m, C3’H, C4’H, C5’H, C2”H, C6”H),
7.20 (2H, dd, J 7.5, J 1.3, C2’H, C6’H), 6.71 (1H, d, J 8.0,
4.4.1. 1,8-Dimethoxy-9,10-diphenylacridinium
3
4
3
bromide salt (4a-Br– )
3
4
C7H), 6.51 (1H, d, J 8.6, C5H), 6.41 (1H, d, J 1.1, C2H), 5.42
4
The compound was prepared according to the general
procedure A and B using 3-methoxy-N-(3-methoxyphenyl)-N-
phenylaniline (1a) (48.9 mg, 160 µmol) and methyl
benzoate (13.6 mg, 100 µmol) and was stirred 12 h at RT.
Purification gave a brown red solid (20.1 mg, 43%, HPLC purity:
95.2%;19 decomp. at 115 °C): Rf 0.19 (CH2Cl2:MeOH 10:1);
νmax (neat): 2999w, 1586s, 1462s, 1363m, 1265s, 1248s, 1198w,
(1H, d, J 1.1, C4H), 3.52 (3H, s, OCH3), 3.38 (3H, s, OCH3),
3.19 (6H, br, N(CH3)2); 13C NMR (125 MHz, CDCl3): δ = 161.3
(C1), 160.0 (C8), 157.3 (C3), 156.1 (C9), 145.4 (C4a), 142.0
(C10a), 141.6 (C1’), 138.7 (C1”), 136.2 (C6), 132.0 (C3”, C5”),
131.0 (C4”), 128.0 (C2”, C6”), 126.8 (C3’, C5’), 126.7 (C4’),
125.9 (C2’, C6’), 115.5 (C9a), 114.7 (C8a), 109.6 (C5), 105.7
(C7), 95.8 (C2), 89.1 (C4), 57.0 (C1OCH3), 56.3 (C8OCH3), 41.3
1
+
1082s, 982w, 925w, 811m, 758s, 738s, 696s, 655m; H NMR
(N(CH3)2); ESI-MS: m/z calcd. for C29H27N2O2 435.2067 found
3
435.2073 [M+]. Luminescence spectroscopy (in MeCN): λabs1
:
:
(500 MHz, CDCl3): δ = 8.02 (2H, t, J 8.4, C3H, C6H), 7.89–
: 430 nm; εabs1:
8.6·103 L·cm·mol–1; εabs2
7.91 (2H, m, C3”H, C5”H), 7.83–7.86 (1H, m, C4”H), 7.64–7.66
(2H, m, C2”H, C6”H), 7.44–7.50 (3H, m, C3’H, C4’H, C5’H),
7.33–7.34 (2H, m, C2’H, C6’H), 7.03 (2H, d, 3J 7.9, C2H, C7H),
501 nm; λabs2
1.6·104 L·cm·mol–1, λem(exc 491): 584 nm; λem(exc 420): 589
nm; Stokes shift: 83 nm; E0,0: 2.25 eV; <τF>: 4.7 ns; Cyclic
voltammetry (vs SCE): E1/2(P*/P–): +1.31 V, E1/2(P/P–): –0.94 V.
4
6.92 (2H, dd, 3J 8.9, J 0.6, C4H, C5H), 3.52 (6H, s, 2 x OCH3);
13C NMR (125 MHz, CDCl3): δ = 163.3 (C9), 160.2 (C1, C8),
142.8 (C4a, C10a), 141.3 (C1’), 140.4 (C3, C6), 138.4 (C1”),
131.8 (C3”, C5”), 131.6 (C4”), 127.9 (C2”, C6”), 127.2 (C4’),
126.9 (C3’, C5’), 125.7 (C2’, C6’), 119.1 (C8a, C9a), 110.9 (C4,
C5), 107.1 (C2, C7), 56.9 (2 x OCH3); ESI-MS: m/z calcd. for
4.4.4. 3,6-Bis(dimethylamino)-1,8-dimethoxy-9,10-
diphenylacridinium bromide salt (4c)
The compound was prepared according to the general
procedure
A
and
B
using N1-(3-(dimethylamino)-5-
+
C27H22NO2 392.1645 found 392.1648 [M+]. Luminescence
methoxyphenyl)-5-methoxy-N3,N3-dimethyl-N1-phenylbenzene-
1,3-diamine (1c) (62.6 mg, 160 µmol) in n hexane:Et2O (2.2 mL,
10:1) and methyl benzoate (13.6 mg, 100 µmol) and was stirred
14 h at RT. Purification gave a brown red solid (19.7 mg, 35%,
HPLC purity: 78.7%;19 decomp. at 148 °C): Rf 0.17
(CH2Cl2:MeOH 10:1); νmax (neat): 2925w, 2360w, 2166w, 1599s,
spectroscopy (in MeCN): λabs1: 503 nm; λabs2: 409 nm; εabs1
:
4.4·103 L·cm·mol–1; εabs2: 5.8·103 L·cm·mol–1, λem(exc 493): 595
nm; λem(exc 399): 591 nm; Stokes shift: 92 nm; E0,0: 2.23 eV;
<τF>: 3.1 ns; Cyclic voltammetry (vs SCE): E1/2(P*/P–): +1.76 V,
E1/2(P/P–): –0.47 V.
1
1490m, 1433w, 1333m, 1254s, 975w, 923w, 781m, 630w; H
4.4.2. 1,8-Dimethoxy-9,10-diphenylacridinium
NMR (500 MHz, CDCl3): δ = 7.82–7.85 (2H, m), 7.73–7.76 (1H,
m), 7.38–7.40 (4H, m, C2’H, C6’H, C2”H, C6”H), 7.33–7.36
(1H, m), 7.17–7.18 (2H, m), 6.07 (2H, d, 4J 1.9, C2H, C7H), 5.36
(2H, d, 4J 1.8, C4H, C5H), 3.38 (6H, s, 2 x OCH3), 3.00 (12H, s,
2 x N(CH3)2); 13C NMR (125 MHz, CDCl3): δ = 161.3 (C1, C8),
155.4 (C3, C6), 154.6, 144.9 (C4a, C5a), 142.2 (C9), 139.2,
131.9, 130.6, 128.1, 126.7, 126.3, 126.0, 109.8 (C8a, C9a), 93.3
(C2, C7), 89.5 (C4, C5), 56.1 (OCH3), 40.3 (N(CH3)2); ESI-MS:
–
tetrafluoroborate salt (4a-BF4
)
The compound was prepared according to the general
procedure A and B using 3-methoxy-N-(3-methoxyphenyl)-N-
phenylaniline (1a) (48.9 mg, 160 µmol) and methyl
benzoate (13.6 mg, 100 µmol) and was stirred 12 h at RT and
treated with aq. HBF4 (50%, 1.00 mL) instead of aq. HBr.
Purification gave a brown red solid (21.3 mg, 44%, HPLC purity:
97.2%; decomp. at 140 °C): Rf 0.28 (CH2Cl2:MeOH 10:1);
νmax (neat): 3060w, 2938w, 1581m, 1501m, 1464m, 1434m,
1362m, 1266s, 1198w, 1048s, 910w, 819w, 748s, 698m; 1H
+
m/z calcd. for C31H32N3O2 478.2489 found 478.2495 [M+].
Luminescence spectroscopy (in MeCN): λabs: 498 nm; εabs
:
4.0·104 L·cm·mol–1; λem(exc 488): 540 nm; Stokes shift: 42 nm;
E0,0: 2.40 eV; <τF>: 4.4 ns; Cyclic voltammetry (vs SCE):
E1/2(P*/P–): +1.21 V, E1/2(P/P–): –1.19 V.
3
NMR (600 MHz, CDCl3): δ = 7.94 (2H, dd, J 8.9, 8.1, C3H,
C6H), 7.82–7.88 (3H, m, C3”H, C4”H, C5”H), 7.55–7.56 (2H,
m, C2”H, C6”H), 7.42–7.48 (3H, m, C3’H, C4’H, C5’H), 7.31–
7.33 (2H, m, C2’H, C6’H), 6.98 (2H, d, 3J 8.0, C2H, C7H), 6.89
4.4.1. 1,8-Dimethoxy-10-methyl-9-phenylacridinium
bromide salt (4d)
3
(2H, d, J 9.0, C4H, C5H), 3.49 (6H, s, 2 x OCH3); 13C NMR
(151 MHz, CDCl3): δ = 163.4 (C9), 160.2 (C1, C8), 142.7 (C4a,
C10a), 141.4 (C1’), 140.9 (C3, C6), 138.4 (C1”), 131.7 (C3”,
C5”), 131.5 (C4”), 127.8 (C2”, C6”), 127.1 (C4’), 126.9 (C3’,
C5’), 125.6 (C2’, C6’), 119.1 (C8a, C9a), 110.8 (C4, C5), 106.9
(C2, C7), 56.7 (2 x OCH3); 19F NMR (235 MHz, CDCl3): –154.5;
The compound was prepared according to the general
procedure A and B using 3-methoxy-N-(3-methoxyphenyl)-N-
methylaniline (1d) (38.9 mg, 160 µmol) and methyl
benzoate (13.6 mg, 100 µmol) and was stirred 12 h at RT.
Purification gave a brown red solid (19.9 mg, 49%, HPLC purity:
98.6%; decomp. at 150 °C): Rf 0.12 (CH2Cl2:MeOH 10:1);
νmax (neat): 3411w, 1606m, 1504m, 1465m, 1345m, 1260s,
1168m, 1072m, 926w, 816m, 729s, 699s, 632m; 1H NMR
(500 MHz, CDCl3): δ = 8.24–8.28 (2H, m, C4H, C5H), 8.26–
8.30 (2H, m, C3H, C6H), 7.42–7.46 (3H, m, C3’H, C4’H, C5’H),
+
ESI-MS: m/z calcd. for C27H22NO2 392.1645 found 392.1649
[M+]. Luminescence spectroscopy (in MeCN): λabs1: 503 nm;
λabs2: 409 nm; εabs1: 3.2·103 L·cm·mol–1; εabs2: 4.2·103 L·cm·mol–
1, λem(exc 493): 596 nm; λem(exc 399): 592 nm; Stokes shift: 93
nm; E0,0: 2.23 eV; <τF>: 3.4 ns; Cyclic voltammetry (vs SCE):
E1/2(P*/P–): +1.74 V, E1/2(P/P–): –0.49 V.
3
4
7.15–7.17 (2H, m, C2’H, C6’H), 7.01 (2H, dd, J 7.2, J 1.2,
C2H, C7H), 5.02 (3H, s, NCH3), 3.48 (6H, s, 2 x OCH3); 13C
NMR (125 MHz, CDCl3): δ = 161.1 (C9), 160.1 (C1, C8), 142.3
(C4a, C10a), 141.4 (C1’), 140.8 (C3, C6), 127.1 (C4’), 126.8
(C3’, C5’), 125.6 (C2’, C6’), 119.1 (C8a, C9a), 110.2 (C4, C5),
106.8 (C2, C7), 56.6 (2 x OCH3), 42.3 (NCH3); ESI-MS: m/z
4.4.3. 3-(Dimethylamino)-1,8-dimethoxy-9,10-
diphenylacridinium bromide salt (4b)
The compound was prepared according to the general procedure
A
and
dimethyl-N1-phenylbenzene-1,3-diamine
160 µmol) and methyl benzoate (13.6 mg, 100 µmol) and was
B
using 5-methoxy-N1-(3-methoxyphenyl)-N3,N3-
+
calcd. for C22H20NO2 330.1489 found 330.1494 [M+].
(1b)
(55.8
mg,
Luminescence spectroscopy (in MeCN): λabs1: 497 nm; λabs2: 403